Literature DB >> 24389436

Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.

Linda Denehy1, Whitney E Hornsby, James E Herndon, Samantha Thomas, Neal E Ready, Catherine L Granger, Lauren Valera, Aarti A Kenjale, Neil D Eves, Lee W Jones.   

Abstract

INTRODUCTION: To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non-small-cell lung cancer (NSCLC).
METHODS: One hundred consecutive patients with inoperable NSCLC and performance status 0 to 3 completed pulmonary function testing, the modified Medical Research Council dyspnea scale, a 6-minute walk test, and body mass index-the multidimensional 10-point BODE index. Cox proportional models were used to estimate the risk of all-cause mortality according to the BODE index with or without adjustment for traditional prognostic factors.
RESULTS: Median follow-up was 31.5 months; 61 deaths (61%) were reported during this period. There was a significant univariate association between the BODE index score and mortality (adjusted p(trend) = 0.027). Compared with patients with a BODE index of 0, the adjusted hazard ratio for risk of death was 1.37 (95% confidence interval [CI], 0.74-2.55) for a BODE index of 1, 1.22 (95% CI, 0.45-3.25) for a BODE index of 2, and 2.44 (95% CI, 1.19-4.99) for a BODE index more than 2. The BODE index provided incremental prognostic information beyond that provided traditional markers of prognosis (adjusted p(trend) = 0.051). Every one-point increase in the BODE index, the risk of death increased by 25% (hazard ratio = 1.25; 95% CI, 1.27-4.64).
CONCLUSIONS: The BODE index is a strong independent predictor of survival in inoperable NSCLC beyond traditional risk factors. Use of this multidimensional tool may improve risk stratification and prognostication in NSCLC.

Entities:  

Mesh:

Year:  2013        PMID: 24389436     DOI: 10.1097/JTO.0000000000000032

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  6 in total

1.  Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.

Authors:  Despoina Moumtzi; Sofia Lampaki; Paul Zarogoulidis; Konstantinos Porpodis; Kalliopi Lagoudi; Wolfgang Hohenforst-Schmidt; Athanasia Pataka; Theodora Tsiouda; Athanasios Zissimopoulos; George Lazaridis; Vasilis Karavasilis; Helen Timotheadou; Nikolaos Barbetakis; Pavlos Pavlidis; Theodoros Kontakiotis; Konstantinos Zarogoulidis
Journal:  Ann Transl Med       Date:  2016-05

Review 2.  Preoperative exercise training for patients with non-small cell lung cancer.

Authors:  Vinicius Cavalheri; Catherine Granger
Journal:  Cochrane Database Syst Rev       Date:  2017-06-07

3.  Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer.

Authors:  Hisao Imai; Kyoichi Kaira; Keita Mori; Akira Ono; Hiroaki Akamatsu; Shunichi Matsumoto; Tetsuhiko Taira; Hirotsugu Kenmotsu; Hideyuki Harada; Tateaki Naito; Haruyasu Murakami; Masahiro Endo; Takashi Nakajima; Masanobu Yamada; Toshiaki Takahashi
Journal:  BMC Cancer       Date:  2015-12-21       Impact factor: 4.430

4.  Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer.

Authors:  Woo Ho Ban; Jong Min Lee; Jick Hwan Ha; Chang Dong Yeo; Hyeon Hui Kang; Chin Kook Rhee; Hwa Sik Moon; Sang Haak Lee
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

5.  Which field walking test should be used to assess functional exercise capacity in lung cancer? An observational study.

Authors:  Catherine L Granger; Linda Denehy; Selina M Parry; Joel Martin; Tim Dimitriadis; Maeve Sorohan; Louis Irving
Journal:  BMC Pulm Med       Date:  2015-08-12       Impact factor: 3.317

6.  Exercise experiences in patients with metastatic lung cancer: A qualitative approach.

Authors:  Pi-Hua Chang; Ching-Rong Lin; Yun-Hsiang Lee; Yi-Lin Liu; Gee-Chen Chang; Aasha I Hoogland; Yeur-Hur Lai
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.